This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A look at the recent FDA approval of AstraZeneca's Airsupra (albuterol/budesonide) the first and only rescue medication to reduce risk of asthma exacerbations in adults.

Ticker(s): AZN

Who's the expert?

Institution: Allergy and Asthma Center of Minnesota

  • Pediatric Allergist & Immunologist in private practice.
  • Manages over 1000 patients with asthma and 400 with peanut allergy.
  • Double Board certified in Pediatrics & Allergy, Asthma and Immunology; President of the Minnesota Allergy Society and director of Outpatient Allergy at the University of Minnesota.

Interview Questions

Please describe your background and practice setting

Added By: joe_mccann

How many patients with asthma do you currently manage?

Added By: joe_mccann

What percentage of your population are children? Do you think that is typical nationwide?

Added By: joe_mccann

What are your overall thoughts on the approval of Airsupra?

Added By: joe_mccann

How many patients do you expect to prescribe Airsurpa too in the next year?

Added By: joe_mccann

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.